# OnCo record paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017" ;
  schema:name "PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group"@en ;
  schema:alternateName "HD18"@en, "Borchmann 2017"@en ;
  schema:description "People whose scan cleared after two rounds of the most intensive Hodgkin regimen could stop after four rounds instead of six or eight, halving severe infections with no loss of control."@en ;
  schema:url <https://onco.cc/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(17)32134-7>, <https://pubmed.ncbi.nlm.nih.gov/29061295/>, <https://europepmc.org/article/MED/29061295> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(17)32134-7> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Borchmann P, Goergen H, Kobe C, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/chemotherapy/>, <https://onco.cc/fronts/imaging/> ;
  onco:technologies <https://onco.cc/technologies/pet-ct/> ;
  onco:drugs <https://onco.cc/drugs/bleomycin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/ghsg/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/abvd-beacopp/>, <https://onco.cc/terms/non-inferiority/> ;
  onco:trials <https://onco.cc/trials/hd18/>, <https://onco.cc/trials/hd21/> ;
  onco:people <https://onco.cc/people/peter-borchmann/>, <https://onco.cc/people/andreas-engert/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:journals <https://onco.cc/journals/lancet/> .
